Illumina, Inc. (NASDAQ:ILMN - Free Report) - Research analysts at Leerink Partnrs decreased their Q3 2025 earnings per share estimates for Illumina in a report issued on Thursday, April 17th. Leerink Partnrs analyst P. Souda now anticipates that the life sciences company will post earnings per share of $1.05 for the quarter, down from their previous forecast of $1.10. The consensus estimate for Illumina's current full-year earnings is $4.51 per share. Leerink Partnrs also issued estimates for Illumina's Q1 2026 earnings at $1.03 EPS, Q2 2026 earnings at $1.17 EPS, Q3 2026 earnings at $1.30 EPS, Q4 2026 earnings at $1.47 EPS and FY2026 earnings at $4.97 EPS.
Illumina (NASDAQ:ILMN - Get Free Report) last announced its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing analysts' consensus estimates of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%.
A number of other brokerages also recently weighed in on ILMN. HSBC downgraded Illumina from a "buy" rating to a "hold" rating and set a $100.00 price target on the stock. in a report on Friday, February 28th. Stephens restated an "overweight" rating and set a $156.00 price target on shares of Illumina in a report on Tuesday, March 11th. Robert W. Baird cut their price target on Illumina from $127.00 to $90.00 and set a "neutral" rating for the company in a research note on Wednesday, March 5th. Royal Bank of Canada decreased their price target on shares of Illumina from $128.00 to $112.00 and set an "outperform" rating for the company in a report on Tuesday, April 8th. Finally, Morgan Stanley decreased their target price on Illumina from $150.00 to $136.00 and set an "equal weight" rating for the company in a research note on Tuesday, February 11th. One investment analyst has rated the stock with a sell rating, ten have given a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $138.70.
Check Out Our Latest Stock Report on ILMN
Illumina Trading Up 2.9 %
Shares of NASDAQ:ILMN traded up $2.17 during mid-day trading on Friday, hitting $76.52. The stock had a trading volume of 696,658 shares, compared to its average volume of 2,268,859. Illumina has a 12-month low of $68.70 and a 12-month high of $156.66. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.42 and a current ratio of 1.77. The company has a market cap of $12.11 billion, a PE ratio of -9.96, a P/E/G ratio of 1.60 and a beta of 1.38. The company's 50 day moving average is $83.43 and its 200-day moving average is $119.36.
Institutional Trading of Illumina
A number of large investors have recently bought and sold shares of the business. Capital World Investors raised its holdings in Illumina by 408.6% during the fourth quarter. Capital World Investors now owns 18,025,301 shares of the life sciences company's stock worth $2,408,721,000 after acquiring an additional 14,481,232 shares in the last quarter. Brown Advisory Inc. increased its holdings in Illumina by 54,220.9% during the fourth quarter. Brown Advisory Inc. now owns 1,912,639 shares of the life sciences company's stock worth $255,586,000 after buying an additional 1,909,118 shares during the last quarter. Norges Bank acquired a new stake in Illumina in the fourth quarter valued at $228,714,000. Bessemer Group Inc. grew its position in shares of Illumina by 32,837.5% in the 4th quarter. Bessemer Group Inc. now owns 1,348,131 shares of the life sciences company's stock valued at $180,152,000 after acquiring an additional 1,344,038 shares during the period. Finally, Assenagon Asset Management S.A. raised its holdings in shares of Illumina by 2,057.5% in the 1st quarter. Assenagon Asset Management S.A. now owns 922,281 shares of the life sciences company's stock valued at $73,174,000 after purchasing an additional 879,533 shares during the period. 89.42% of the stock is owned by institutional investors.
About Illumina
(
Get Free Report)
Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.
Read More
Before you consider Illumina, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Illumina wasn't on the list.
While Illumina currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
